TY  - JOUR
AU  - Van der Weijst, Lotte
AU  - Aguado-Barrera, Miguel E
AU  - Azria, David
AU  - Berkovic, Patrick
AU  - Boisselier, Pierre
AU  - Briers, Erik
AU  - Bultijnck, Renée
AU  - Calvo-Crespo, Patricia
AU  - Chang-Claude, Jenny
AU  - Choudhury, Ananya
AU  - Defraene, Gilles
AU  - Demontois, Sylvian
AU  - Dunning, Alison M
AU  - Elliott, Rebecca M
AU  - Ennis, Dawn
AU  - Faivre-Finn, Corinne
AU  - Franceschini, Marzia
AU  - Gutiérrez-Enríquez, Sara
AU  - Herskind, Carsten
AU  - Higginson, Daniel S
AU  - Kerns, Sarah L
AU  - Johnson, Kerstie
AU  - Mollà, Meritxell
AU  - Lambrecht, Maarten
AU  - Ramos, Mónica
AU  - Rancati, Tiziana
AU  - Rimner, Andreas
AU  - Rosenstein, Barry S
AU  - De Ruysscher, Dirk
AU  - Salem, Ahmed
AU  - Sangalli, Claudia
AU  - Seibold, Petra
AU  - Sosa-Fajardo, Paloma
AU  - Sperk, Elena
AU  - Stobart, Hilary
AU  - Summersgill, Holly
AU  - Surmont, Veerle
AU  - Symonds, Paul
AU  - Taboada-Lorenzo, Begoña
AU  - Talbot, Christopher J
AU  - Valdagni, Riccardo
AU  - Vega, Ana
AU  - Veldeman, Liv
AU  - Veldwijk, Marlon R
AU  - Ward, Tim
AU  - Webb, Adam
AU  - West, Catharine M L
AU  - Lievens, Yolande
TI  - Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study).
JO  - Lung cancer
VL  - 166
SN  - 0169-5002
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2022-00560
SP  - 228 - 241
PY  - 2022
AB  - Radiotherapy-induced toxicity may negatively impact health-related quality of life (HRQoL). This report investigates the impact of curative-intent radiotherapy on HRQoL and toxicity in early stage and locally-advanced non-small cell lung cancer patients treated with radiotherapy or chemo-radiotherapy enrolled in the observational prospective REQUITE study.HRQoL was assessed using the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire up to 2 years post radiotherapy. Eleven toxicities were scored by clinicians using the Common Terminology Criteria for Adverse Events (CTCAE) version 4. Toxicity scores were calculated by subtracting baseline values. Mixed model analyses were applied to determine statistical significance (p ≤ 0.01). Meaningful clinical important differences (MCID) were determined for changes in HRQoL. Analysis was performed on the overall data, different radiotherapy techniques, multimodality treatments and disease stages.Data of 510 patients were analysed. There was no significant change in HRQoL or its domains, except for deterioration in cognitive functioning (p = 0.01). Radiotherapy technique had no significant impact on HRQoL. The addition of chemotherapy was significantly associated with HRQoL over time (p <.001). Overall toxicity did not significantly change over time. Acute toxicities of radiation-dermatitis (p =.003), dysphagia (p =.002) and esophagitis (p <.001) peaked at 3 months and decreased thereafter. Pneumonitis initially deteriorated but improved significantly after 12 months (p =.011). A proportion of patients experienced meaningful clinically important improvements and deteriorations in overall HRQoL and its domains. In some patients, pre-treatment symptoms improved gradually.While overall HRQoL and toxicity did not change over time, some patients improved, whereas others experienced acute radiotherapy-induced toxicities and deteriorated HRQoL, especially physical and cognitive functioning. Patient characteristics, more so than radiotherapy technique and treatment modality, impact post-radiotherapy toxicity and HRQoL outcomes. This stresses the importance of considering the potential impact of radiotherapy on individuals' HRQoL, symptoms and toxicity in treatment decision-making.
LB  - PUB:(DE-HGF)16
C6  - pmid:35334417
DO  - DOI:10.1016/j.lungcan.2022.03.010
UR  - https://inrepo02.dkfz.de/record/179278
ER  -